Aripiprazole Tablet
Product Images NDC 50228-326

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 50228-326). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sciegen Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-1.jpg (Aripiprazole Figure1)

A chart illustrating the effect of various drugs on Aripiprazole pharmacokinetics, showing fold changes and 90% confidence intervals for AUC and Cmax relative to reference without the interacting drug. The chart compares CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lithium, lorazepam).*

FDA Label Image

Figure-2.jpg (Aripiprazole Figure2)

A pharmacokinetic chart showing the effect of various interacting drugs on Aripiprazole's dehydro-aripiprazole metabolite, measured as fold change in AUC and Cmax with 90% confidence intervals. The x-axis represents change relative to a reference without interacting drug, highlighting impacts of inhibitors, inducers, and other drugs.*

FDA Label Image

Figure-3.jpg (Aripiprazole Figure3)

A scatter plot showing the effect of Aripiprazole on the pharmacokinetics of various other drugs, including dextromethorphan, warfarin (S- and R- enantiomers), omeprazole, lamotrigine, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram. The x-axis represents the fold change relative to reference (no interacting drug) with a 90% confidence interval, illustrating the degree of change in drug exposure metrics such as AUC, Cmax, INR, and DMDRP.*

FDA Label Image

Figure-4.jpg (Aripiprazole Figure4)

A pharmacokinetic chart showing Aripiprazole fold change and 90% confidence intervals for various special populations. It compares parameters AUC and Cmax across categories including CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment relative to reference values.*

FDA Label Image

Figure-5.jpg (Aripiprazole Figure5)

A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing the effect of various factors (CYP2D6 metabolizer status, gender, age, hepatic and renal impairment) on AUC and Cmax values relative to a reference. The horizontal axis measures fold change from 0 to over 3, with data points and confidence intervals plotted for each factor comparison.*

FDA Label Image

Figure-6.jpg (Aripiprazole Figure6)

A Kaplan-Meier curve chart showing the proportion of subjects with relapse over days from randomization for Aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis indicates the proportion with relapse. The chart includes a risk table indicating the number of subjects at risk at several time points for both groups.*

FDA Label Image

Figure 7 (Aripiprazole Figure7)

A Kaplan-Meier curve graph showing the proportion of subjects with relapse over days from randomization comparing Aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. A table below indicates the number of subjects at risk at various time points for both Aripiprazole and placebo groups.*

FDA Label Image

Figure 8 (Aripiprazole Figure8)

A line graph depicting the proportion of subjects with relapse over time, comparing Aripiprazole and placebo groups. The x-axis represents days from randomization, with sample sizes indicated below, while the y-axis shows the proportion of relapse, ranging from 0.0 to 1.0. Solid and dashed lines represent Aripiprazole and placebo, respectively.*

FDA Label Image

2mg-1000 (Aripiprazole Label1)

Aripiprazole Tablets, USP 2 mg oral tablets label by ScieGen Pharmaceuticals Inc. The label indicates a package count of 1,000 tablets and includes storage instructions, pharmacist dispensing guidance, and a barcode. The label highlights the 2 mg strength prominently in green with the NDC number 50228-324-10.*

FDA Label Image

20mg-30 (Aripiprazole Label10)

Aripiprazole Tablets, USP 20 mg oral tablets in a 30-tablet package. The label includes dosage and storage instructions, a barcode, lot and expiration placeholders, and notes the product is Rx only. Manufactured by ScieGen Pharmaceuticals Inc., Hauppauge, NY.*

FDA Label Image

30mg-1000 (Aripiprazole Label11)

Label for Aripiprazole Tablets, USP 30 mg oral tablets by ScieGen Pharmaceuticals Inc. The label states each tablet contains 30 mg of aripiprazole and includes dosage, storage instructions, and a 1,000 tablets quantity. It also features a barcode, NDC 50228-329-10, and specifies Rx only.*

FDA Label Image

30mg-30 (Aripiprazole Label12)

Label for Aripiprazole Tablets, USP 30 mg oral tablets by ScieGen Pharmaceuticals Inc. The label includes dosage information, storage instructions, a barcode, and states the package contains 30 tablets. It also displays the NDC number 50228-329-30 and cautions to keep medication out of reach of children.*

FDA Label Image

2mg-30 (Aripiprazole Label2)

Aripiprazole Tablets USP, 2 mg strength, oral tablet dosage form, packaged by ScieGen Pharmaceuticals Inc. The label indicates a package of 30 tablets with prescription-only status. It includes storage instructions, a bar code, lot and expiration placeholders, and pharmacist dispensing guidance. The NDC number 50228-324-30 is shown.*

FDA Label Image

5mg-1000 (Aripiprazole Label3)

Label for Aripiprazole Tablets USP 5 mg from ScieGen Pharmaceuticals Inc. The label indicates a package quantity of 1,000 tablets and includes the NDC 50228-325-10. Storage instructions specify keeping tablets in tightly closed containers at 25°C with permissible excursions. A barcode and a note 'NO VARNISH' appear on the label, along with reminders about dispensing the Medication Guide and medication safety for children.*

FDA Label Image

5mg-30 (Aripiprazole Label4)

Aripiprazole Tablets, USP 5 mg oral tablets by ScieGen Pharmaceuticals Inc. The label states storage instructions, usual dosage advises reading prescribing information, contains 30 tablets per container, and includes a barcode and manufacturer details from Hauppauge, NY.*

FDA Label Image

10mg-1000 (Aripiprazole Label5)

Label for Aripiprazole Tablets USP, 10 mg strength, manufactured by ScieGen Pharmaceuticals Inc. The label states each tablet contains 10 mg of aripiprazole and instructs storage at 25°C with permitted excursions. It notes the quantity as 1,000 tablets and indicates the product is Rx only. Additional information includes a barcode and a note to dispense the medication guide separately to each patient.*

FDA Label Image

10mg-30 (Aripiprazole Label6)

Aripiprazole Tablets, USP 10 mg oral tablets packaging label by ScieGen Pharmaceuticals Inc. The label includes dosage form, strength, NDC 50228-326-30, quantity of 30 tablets, and storage instructions. It also includes pharmacist dispensing instructions, barcode, and manufacturer information.*

FDA Label Image

15mg-1000 (Aripiprazole Label7)

Label for Aripiprazole Tablets USP 15 mg by ScieGen Pharmaceuticals Inc. The label states 1,000 tablets per container, storage instructions at 25°C with permitted excursions, and a pharmacist notice to dispense the medication guide. It includes the NDC 50228-327-10 and manufacturer information with barcode.*

FDA Label Image

15mg-30 (Aripiprazole Label8)

This text panel for Aripiprazole Tablets USP provides dosage strength (15 mg), storage instructions (keep tightly closed at 25°C with permitted excursions), and a pharmacist instruction to dispense the enclosed Medication Guide. It includes caution to keep the medication out of children's reach, packaging size (30 tablets), and manufacturer info for ScieGen Pharmaceuticals, Inc.*

FDA Label Image

20mg-1000 (Aripiprazole Label9)

Aripiprazole Tablets USP, 20 mg strength, packaged as 1,000 tablets for oral use. The label shows the product name prominently with dosage strength in a box. Manufacturer is ScieGen Pharmaceuticals Inc. Storage instructions indicate controlled room temperature. The label includes a barcode and states 'Rx Only'.*

FDA Label Image

Structural Formula (Aripiprazole Structure)

Chemical structure of Aripiprazole, showing two connected cyclic systems including a dichlorophenyl group and a quinolinone moiety linked by a piperazine ring and an ethoxy chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.